Switch to
More onapp

How to use scorecard? Learn more

Windlas Biotech Ltd

WINDLAS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,291 cr, stock is ranked 1,098
High RiskStock is 3.75x as volatile as Nifty
1,052.7012.65 (-1.19%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,291 cr, stock is ranked 1,098
High RiskStock is 3.75x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
37.42
PB RatioPB Ratio
5.09
Dividend YieldDiv. Yield
0.50%
Sector PESector PE
51.53
Sector PBSector PB
6.56
Sector Div YldSctr Div Yld
0.52%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company provides pharmaceutical development services. It provides contract manufacturing services for pharmaceutical industrialists and also focuses on product development and manufacturing capabilities in generic products.

Investor PresentationView older 

Nov 12, 2024

PDF
View Older Presentations

Financial TrendFinancial statements 

2021202220232024436.34472.64523.05644.4315.8238.0942.6458.18
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Decreased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.13%

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Clarification - Financial Results 
Announced OnDec 11, 2024
The Exchange has sought clarification from Windlas Biotech Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
The Exchange has sought clarification from Windlas Biotech Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnNov 22, 2024

Windlas Biotech Limited has informed the Exchange about Schedule of meet | Download

Windlas Biotech Limited has informed the Exchange about Schedule of meet | Download

Cash Dividend 
Ex. DateSep 17, 2024

Final • Div/Share: ₹ 5.5

See all events